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1. Introduction 
Diabetes mellitus is a metabolic disorder that is characterized by high blood sugar and it is 
because of either problem in insulin secretion (type 1-ǃ cell destruction) or either because of 
combination of insulin resistance or improper insulin secretion to compensate (type 2). 
(Riaz, S. 2009) 
2. Mechanism of action 
Despite ingestion of dietary carbohydrates, serum glucose level remain relatively steady 
throughout the day. This requires the concerted actions of several different tissues. 
Pancreatic ǃ-cells, for example, secrete insulin in response to the elevation in glucose that 
occur after eating. Insulin promotes glucose disposal in adipose tissue and muscle, and also 
prevents the liver from producing more glucose by suppressing glycogenolysis and 
gluconeogenesis. In the fasting state, low insulin levels combined with elevated counter-
regulatory hormones such as glucagon, adrenaline and corticosteroids promote hepatic 
glucose production. Recently, evidence has emerged that the brain coordinates many of 
these effects as well, through direct and indirect glucose sensing and neural outputs to 
peripheral organs.  
Diabetes results from the dysregulation of multiple glucoregulatory hormones that normally 
acto to maintain glucose homeostasis. For example any defect in insulin production lead to 
improper regulation of glucose in the blood and result in diabetes. Similarly in patients with 
type1 and type 2 diabetes, post prandial glucagon secretion is abnormally elevated. This 
inappropriate secretion of glucagon leads to excess hepatic glucose production and is 
important contributor to postprandial hyperglycemia in patients with diabetes. 
3. Insulin resistance 
Deficient insulin action results from inadequate insulin secretion or decrease the tissue 
response.Insulin resistance is define as lack of sufficient insulin receptors, in target tissue, 
defect in intracellular transport of glucose and or an altered insulin secondary pattern that is 
dys-synchronization between pancreatic ǃ cell release of insulin and the body's insulin 
requirement.( Defronzo, R.A., 1992) 
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Fig. 1. Glucose homeostasis 
4. Prevalence of diabetes 
As the prevalence of diabetes is exponentially increasing in many parts of world. It is 
estimated by WHO that until 2025 there will be 300 million diabetics from which 75% will be 
from developing countries. 
In terms of number of people with diabetes mellitus by the year 2025 USA will be most 
leading country while Pakistan will be at forth country in the list after China and USA. 
(Jawaid, S. A., 2002). According to a new publication released by World Health 
Organization (WHO) and International Diabetes Federation (IDF) 3.2million deaths occur 
because of diabetes. ( Launch of "Diabetes action Now" 5May 2004Ιgeneva) And it is six 
leading cause of death by disease world wide. 
There are several factors that contribute in increasing the prevalence of diabetes thy 
include: 
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 Increase population growth 
 Aging 
 Urbanization 
 Increasing prevalence of obesity 
 Increasing prevalence of physical inactivity. (King, H., and Rewers, M., 1993.) 
5. Etiologic classification of diabetes mellitus 
The World Health Organization (WHO) Expert Committee on diabetes in 1980 and later 
WHO study group on diabetes mellitus approve the recommendation of National Diabetes 
Data Group (NDDG). (Report of a WHO Study Group1985) They divide diabetes mellitus 
into 4 different types : 
1. Insulin dependant diabetes mellitus(IDDM) 
2. Non-insulin dependant diabetes mellitus(NIDDM) 
3. Gestational diabetes mellitus(GDM)  
4. Other types 
5.1 Type 1 diabetes 
5.1.1 Immune mediated diabetes 
This is also called as insulin dependand diabetes or juvenile onset diabetes. In this type 
autoimmunity cause the destruction of ǃ-cells of pancreas. Marker for immune mediated 
diabetes include islet cell autoantibodies (ICAs), autoantibodies to insulin (IAA), 
autoantibodies to glutamic acid decarboxylase(GAD65) and autoantibodies to tyrosine 
phosphatase 1A-2 and 1A-2ǃ. For survival these patients are insulin dependant.  
5.1.2 Idiopathic diabetes 
In this case there is no known reason and these patients have mostly African or Asian origin. 
This is strongly inherited but not HLA associated. They are also insulin dependant.  
5.2 Type 2 diabetes 
This is also known as non-insulin dependant diabetes mellitus or adult onset diabetes. For 
survival of these patients insulin is not necessary.In these patients obesity is a major cause of 
insulin resistance while increase age and physical inactivity are also important 
factors.Ketoacidosis occur because of stress of other infection. it has strong genetic 
predisposition (Riaz, S. 2009).  
5.3 Other specific types of diabetes 
5.3.1 Genetic defect of β cell 
This is also called as maturity onset diabetes of young (MODY), as it appears before age 25 
years and it is characterized by defect in β cell function. In some families inabilityto convert 
proinsulin to insulin while in some cases mature insulin molecule production. 
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5.3.2 Genetic defect in insulin action 
Metabolic abnormalities cause the mutations in insulin receptor. For example in type A 
insulin resistance, leprechaunism, Rabson, Mendenhall syndrome are two pediatric 
syndromes that have mutation in insulin receptor and have extreme insulin resistance. 
5.3.3 Disease of exocrine pancreas 
Injury to pancreas can cause diabetes and it include pancreatitis, trauma, infection, 
pancreatectomy and pancreatic carcinoma 
Endocrinopathy 
Excess amount of some hormone like growth hormone, cortisol, glucagon, apinephrine can 
cause diabetes as they are antagonize insulin action.  
Drug or chemical induce diabetes 
Impairinsulin secretion or insulin resistance also cause by some drugs. For example vacor 
(rat poison), pentamidine, nicotinic acid, glucocorticoids, thyroid hormones, diazoxide, ǃ 
adrenergic agonists, dilantin,ǂ interferon and other.  
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Fig. 2. Etiologic classification of diabetes mellitus 
www.intechopen.com
 
Study of Diabetic Hypertensive Nephropathy in the Local Population of Pakistan 
 
151 
Infection 
Some viruses cause the ǃ  cell destruction. They include congenital rubella, coxsackie virus 
B, cytomegalovirus, adenovirus and mumps.  
Uncommon 
Two conditions are known for it. 
1. in stiffman syndrome glutamic acid decaroxylase autoantibodies are produced.  
2. antiinsulin receptor antibodies bind with insulin receptor and these antibodies are 
present in some autoimmune disease and systemic lupus erythemoatosus. 
5.3.4 Other genetic syndrome 
Incidence of diabetes mellitus also increase with many genetic syndromes. For example 
Down syndrome, Turner's syndrome, Kline-felter's syndrome, Wolfram's syndrome, 
Huntington's chorea, Porphyria etc. Autopsy shows the absence of ǃ cells.  
5.4 Gestational diabetes mellitus 
Impair glucose tolerance normally occur in third trimester of pregnancy. (O'Sullivan and 
Mahan 1964) Complications of gestational diabetes mellitus increase risk of cesarean 
delivery and chronic hypertension.  
6. Long term complications of diabetes 
Long term complications of diabetes include the: 
 retinopathy (potential loss of vision) 
 nephropathy (renal failure) 
 peripheral neuropathy (risk of foot ulcer) 
 autonomic neuropathy cause gastrointestinal, genitourinary and cardiovascular 
symptoms 
 periodontal disease(disease of bone and tissue supporting teeth) 
 and sexual dysfunction. (Report of the Expert Committee on the Diagnosis and 
classification of Diabetes Mellitus) 
6.1 Nephropathy  
Nephropathy is a damage or disease of the kidney. It may be because of several factors and 
diabetes is one of the major factor of nephropathy. 
6.2 Diabetes and nephropathy 
Diabetes nephropathy is microvascular complication that associate with diabetes it slowly 
deteriorate the kidney and lead to end stage renal disease that is chronic and irreversible. 
Diabetic nephropathy need for chronic dialysis or a kidney transplant. 
Since recovery is irreversible so early detection is effective prevention tool. (American 
diabetes association diabetic nephropathy diabetic care 2002; 25 (supplement) 
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6.3 Symptoms of diabetic hypertensive nephropathy 
Diabetic hypertensive nephropathy is characterized by 
 polyuria (frequent urination) 
 polydipsia and polyphagia (excess thirst and food intake) 
 weight loss 
 blurred vision 
 and susceptibility to infection 
 Biochemical changes in diabetic patients 
 Glycation of macromolecules and tissue proteins 
 Risk of cardiovascular peripheral vascular and cerebrovascular disease 
 Abnormalities of lipoproteins metabolism (hypertension) 
 Psychosocial dysfunction also produce because of social impact of diabetes. 
(Report of the Expert Committee on the Diagnosis and classification of Diabetes 
Mellitus) 
6.4 Prevalence of diabetic hypertensive nephropthy 
40% of type 1 and 20% type 2 diabetic patients develop the nephropathy. While prevalence 
of hypertension in type 2 diabetic patients is estimated at 50% with one estimated as high as 
74%. (Riaz, S et al. 2009) 
6.5 Sources of urinary proteins  
The total urinary protein excreted 
- 48% was contained in sediments 
- 49% was soluble 
- and the remaining 3% was in exosomes(Zhou, H., 2006) 
6.5.1 Soluble proteins  
6.5.1.1 Glomerular filteration of plasma proteins 
From glomerular filteration urinary soluble proteins are derived. In proximal tube most of 
the proteins and peptides are scavenged by highly specialized apical uptake process and 
this process involves receptor like recognition of peptide molecules. (Christensen, E. I., and 
Birn, H. 2001; Christensen, E. I. 2002). So in final urine the mount of soluble proteins changes 
with change concentration in blood plasma, change in glomerular filteration and change in 
proximal tubule scavenging system. 
Based on mechanism change in excretion rate of protein indicative of systemic disease, 
globular disease or tubular disease. 
6.5.1.2 Epithelial cell secretion of soluble proteins 
Some proteolytically cleaved membrane bound proteins also present in urine. One of them 
is Tamm-Horsfall protein. It is most abundant protein in urine and if it is not removed its 
presence interfare with detection of other proteins. 
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6.5.2 Solid phase components 
Solid phase components consist of sediments that can be precipitated at low centrifugation. 
It mainly consist of epithelial cells. They are important for diagnostic information because 
increase number of these cells indicates the renal disease. 
6.5.3 Exosomes 
Exosomes are derived from glomerular podocytes, renal tubule cells from proximal and 
distal nephron segments and transitional epithelial cell lining the urinary drainage system. 
Exosome are the internal vesicles of multivasculr bodies and transfer to extracellular fluid 
by fusion of outer membrane of multivesicular bodies with plasma membrane. (Pisitkun, T., 
2004) 
6.6 Urinary protein marker for diabetic nephropathy 
Urinary protein profiling can reveal changes in excretion rates of specific proteins that can 
have predictive value in the clinical arena, for example 
 In the early diagnosis of disease 
 In classification of disease with regard to likely therapeutic responses 
 In assessment of prognosis 
 and in monitoring response to therapy 
6.7 Up-regulated urinary proteins in diabetic nephropathy 
6.7.1 Albumin and non-immunoreactive albumin 
The molecular weight of albumin is 71,658 KDa. Clinically, diabetic nephropathy can be 
diagnosed when albumin is detected in the urine (albumin excretion 30–300 mg/day). The 
presence of albumin in the urine is considered predictive of the subsequent development 
and clinical progression of diabetic nephropathy. (The Microalbuminuria Collaborative 
Study Group)  Microalbuminuria is not specific for diabetic nephropathy , since albumin can 
also be detected in some other pathological conditions and the prevalence of 
microalbuminuria in the general population is rather high. Finally, microalbuminuria is a 
poor predictor of diabetic nephropathy.(Riaz, S et al., 2010) 
6.7.2 α1B-Glycoprotein 
The molecular weight of ǂ1B-Glycoprotein is 54,239 KDa. It is homologous to the 
immunoglobulin supergene family and contains five Ig-like V type (immunoglobulin-like) 
domains. ǂ1B-glycoprotein binds heme and transports it to the liver for breakdown and iron 
recovery, after which the free hemopexin returns to the circulation. ǂ1B-Glycoprotein has 
possible role in the autoimmunity involved in nephropathy. Its levels have been described 
to be higher in type 2 diabetes, its relationship with C-reactive protein is lost in both type 1 
and type 2 diabetes, and its levels are independently determined by triacylglycerol and the 
diabetic state (Van Campenhout, A., et al 2006). This molecule can potentially act as a toxic 
protease, leading in the rat to proteinuria and glomerular alterations (Bakker, W.W., et al 
2005). Although there were no direct references to its possible effects in humans with 
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diabetes or nephropathy, because diabetes is an inflammatory condition associated with 
iron abnormalities, it can be postulated that ǂ1B-Glycoprotein is altered in diabetes. 
6.7.3 Zinc-α2-glycoprotein 
The molecular weight of Zinc-ǂ2-glycoprotein is 34,223 KDa. . This protein stimulates lipid 
degradation in adipocytes and may also bind polyunsaturated fatty acids. Zinc-ǂ2-
glycoprotein was the second most abundant urinary protein in diabetic nephropathy. An 
earlier study of type 2 diabetes described zinc-ǂ2-glycoprotein and three other proteins, ǂ1-
acid glycoprotein, ǂ1- microglobulin, and IgG, as specific markers for diabetic nephropathy 
(Jain, S., et al 2005). 
6.7.4 α2-HSglycoprotein precursor (fetuin A) 
The molecular weight of ǂ2-HSglycoprotein is 39,300KDa. ǂ2-HSglycoprotein precursor is 
an inflammation-related calcium regulatory glycoprotein that acts as a systemic calcification 
inhibitor. Both chronic inflammation and uremia may contribute to exhausting fetuin A 
release in the late stages of kidney disease. Deficiencies of calcification inhibitors such as 
fetuin A are relevant to uncontrolled vascular calcification and may offer potential for future 
therapeutic approaches (Ketteler, M., 2005). 
6.7.5 Vitamin D binding protein (VDBP) 
The molecular weight of vitamin D binding protein is 52,964KDa. Vitamin D binding 
protein is a multifunctional protein found in body fluids and on the surface of many cell 
types. In plasma, it carries vitamin D sterols and prevents polymerization of actin by 
binding its monomers. VDBP also associates with membrane bound immunoglobulin on the 
surface of B lymphocytes and with IgG Fc receptors on the membranes of T lymphocytes, 
suggesting its possible role in the immunepathogenesis and progression of the disease. 
Vitamin D binding protein was also found in the vitreous in diabetic macular edema, along 
with pigment epithelium-derived factor, apoA-4, apoA-1, trip-11, and plasma retinol-
binding protein (RBP). These chemical mediators in the posterior vitreous may play a role in 
the pathogenesis of diabetic macular edema (Ouchi, M., et al 2005). 
6.7.6 Calgranulin B 
The molecular weight of calgranulin is 13,234KDa. Calgranulin B is expressed by 
macrophages in inflamed tissues and is an inhibitor of protein kinases. Differences in the 
isoforms and abundance of several urine proteins, including calgranulin B, inter-ǂ-trypsin 
inhibitor, prothrombin fragment 1, and CD59, were known to be associated with stone 
formation (Bergsland, K. J., et al 2006). There have been no previous reports on their 
association with diabetes or other renal diseases. A1AT is an inhibitor of serine proteases, 
and its primary target is elastase, but it also has a moderate affinity for plasmin and 
thrombin. The serum levels of A1AT and a ǂ1-acid glycoprotein, as well as their 
glycosylated protein fractions, were reported to be significantly greater in sera from 
patients with diabetic nephropathy compared with healthy adults. Marked linear 
deposition of these proteins in the glomerular or dermal vascular walls was also observed 
in the same patients (Inoue, W., 1989), linking them to diabetic nephropathy. Whereas the 
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association between A1AT deficiency and glomerulonephritis has been reported only 
sporadically.  (Os, I., et al 1997). 
6.7.7 Type IV collagen 
The molecular weight of Type IV collagen is 500,000. Type IV collagen is the major 
component of the glomerular extracellular matrix and the level of type IV collagen in the 
urine might reflect the rate of matrix turnover in diseased kidneys. Findings indicate that 
type IV collagen has a specificity for diabetes nephropathy that albumin itself has not, but 
since urinary collagen IV is detectable only when microalbuminuria is already present.( 
Tomino, Y., et al.,  2001) 
6.7.8 Podocytes and nephrin  
Podocytes are key structural elements of the glomerular filtration barrier. Podocytes and 
podocyte-specific proteins can be potentially interesting urinary markers for the early 
diagnosis of an alteration of the glomerulus.( Dalla Vestra, M., et al 2003) Indeed, urinary 
podocytes have been detected only in the urine of diabetic patients with micro- and 
macroalbuminuria, whereas they were absent in healthy controls, type 2 diabetes patients 
without microalbuminuria or patients suffering from chronic renal failure.( Nakamura, T., et 
al 2000). Nephrin is one of the many podocyte-specific proteins that have been described in 
the last few years. nephrin was totally absent in the urine of non-diabetic patients. 
6.7.9 Advanced glycation end products  
Advanced glycation end products (AGEs) are a heterogeneous group of proteins and lipids 
to which sugar residues are covalently bound during physio-pathological processes. 
Kidneys are thought to be one of the key organs for the clearance of AGEs. In type 2 diabetes 
serum low molecular weight advance glycation end products are usually higher than non-
diabetic.( Turk, N., et al., 2004) 
6.7.10 Betaig-h3 
The molecular weight of intact Betaig-h3 is 68KDa. Betaig-h3 is an extracellular matrix 
protein that is induced by transforming growth factor beta, a growth factor implicated in the 
pathogenesis of diabetic nephropathy. Ha et al.( Ha, S. W., et al., 2004) first showed that the 
betaig-h3 to creatinine ratio is significantly higher in type 2 diabetes patients than in control 
subjects. In another study,( Cha, D. R., et al., 2005) it was also observed that the urinary level 
of betaig-h3 is higher in diabetic patients (betaig-h3/creatinine ratio: 25.02 ± 8.84) than in 
healthy individuals (18.67 ± 6.56). 
6.7.11 L1 cell adhesion molecule (CD171) 
L1 cell adhesion molecule (CD171) is a potential new marker for tubular injury. It is 
expressed in human acute kidney injury and excreted in urine. In normal kidney L1 is 
located in basolateral membrane in all epithelial cells of collecting duct except for 
intercalated cells. In acute tubular necrosis, L1 lost its polarized distribution and induce in 
thick ascending limb and distal tubule cells. 
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6.7.12 Tamm-Horsfall protein 
The molecular weight of Tamm-Horsfall protein is 95KDa. It is produced by ascending limb 
of loop of Henle. It is most prevalent protein and excretion rate is 25-40mg/day.( Cvoriscec, 
D., et al., 1985). In renal disease as number of tubules decrease excretion of this protein also 
accordingly decrease.  
6.8 Downregulated urinary proteins in diabetic nephropathy 
6.8.1 Transthyretin (prealbumin) 
The molecular weight of transthyretin is 15,877KDa. Transthyretin (prealbumin) is a thyroid 
hormone-binding protein, which transports a small part of thyroxine from the bloodstream 
to the brain. About 40% of plasma transthyretin circulates in a tight complex with plasma 
RBP. Transthyretin was reported as a better and suitable marker for nutrition assessment in 
patients with chronic renal failure (Saito, K., et al., 2004). Elevated plasma RBP in insulin-
resistant humans with obesity and type-2 diabetes was known to induce hepatic expression 
of the gluconeogenic enzyme phosphoenolpyruvate carboxykinase and impairs insulin 
signaling in muscle (Yang, Q., et al., 2005). It is possible that low RBP-4 in diabetic 
nephropathy increases insulin sensitivity and causes spontaneous hypoglycemia, because 
low RBP-4 is potentially hypoglycemic. (Riaz, S et al., 2010) 
6.8.2 AMBP proteins 
The molecular weight of AMBP is 38,974KDa. AMBP contains both ǂ1-microglobulin and 
inter-ǂ-trypsin inhibitor light chain (bikunin). Bikunin is an important anti-inflammatory 
substance to modulate inflammatory events. Decreases level of this protein affect 
immunocompetence in diabetic renal disease remains unstudied. The other component of 
AMBP protein, ǂ1-microglobulin, in urine was directly related to progressive albuminuria 
in Chinese, Malays, and Asian Indians with type 2 diabetes (Hong, C. Y., et al 2003). This is 
in contrast to the decreasing levels of this protein observed in our study. Urinary ǂ1-
microglobulin indicates proximal tubular dysfunction and could be a useful biomarker for 
the early detection of nephropathy in diabetic subjects in addition to albuminuria, which 
indicates glomerular dysfunction.  
6.8.3 ApoA-I 
The molecular weight of ApoA-I is 30,759KDa. ApoA-I acting as a cofactor for the lecithin 
cholesterol acyltransferase, participates in the reverse transport of cholesterol from tissues to 
the liver for excretion.ApoA1, as well as apoB/A1, was included among several 
nontraditional cardiovascular risk factors in the progression to pediatric metabolic 
syndrome (Retnakaran, R., et al., 2006), but there have been no reported references to its 
association with diabetes or nephropathy. (Riaz, S et al., 2010) 
6.8.4 Adiponectin  
The molecular weight of adiponectin is 28KDa. Adiponectin is an adipocyte-secreted 
cytokine (adipokine) of human plasma. Decreased adiponectin plasma levels are linked to 
obesity, insulin resistance and type 2 diabetes. Koshimura et al. found, in the urine of type 2 
www.intechopen.com
 
Study of Diabetic Hypertensive Nephropathy in the Local Population of Pakistan 
 
157 
diabetes patients with macroalbuminuria, a 30 kDa protein immunoreactive towards an 
anti-adiponectin monoclonal antibody.( Koshimura, J., et al 2004) Urinary adiponectin may 
result from the elevation of the serum concentration and enhanced filtration through the 
damaged kidney. Similar findings were more recently obtained, showing that both serum 
and urinary adiponectin concentrations are elevated in type 2 diabetes patients with 
nephropathy, as compared to patients with microalbuminuria alone.( Fujita, H., et al., 2006) 
7. Hypertensive nephropathy 
This is a condition in which kidney damage occur due to chronic blood pressure. In diabetic 
patients major risk factor for cardiovascular morbidity and mortality is hypertension. 
(Hypertension in Diabetes Study (HDS) 1993 ; Hansson, L., et al 1998) Diabetic nephropathy 
develop in 40% of patients with type 1 diabetes (Krolewski, A. S., et al., 1985) and 35% of 
patients with type 2 diabetes (Mehler, P. S., 1997) rigorous treatment of hypertension slow 
the rate of decrease in renal function and improve mortality (Parving, H. H.,  et al., 1987 ; 
Parving, H., and Hommel, E., 1989) 
7.1 Diabetes and hypertension 
Blood pressure, serum lipids and several cardiovascular factors are effected by central 
adiposity and insulin resistance. (Niaura, R., et al., 2000) Diabetes mellitus and hypertension 
both are associated with high urinary albumin excretion. In type 2 diabetes patients the 
presence of microalbuminuria is often a better predictor of cardiovascular disease than of 
diabetic nephropathy. (Molitch, M. E., et al., 2004) Microalbuminuria is also important 
marker of atheromatosus and potential of coronary heart disease in diabetic patients. 
(Donnelly, R., (2002)  Recommended target blood pressure in all diabetics is ≤130/80 and 
urinary albumin excretion >200mg/l the goal is 125-130/75-80. (Augustine, J., Donald, G., 
diabetic nephropathy (2003) 
7.2 Treatment of nephropathy  
Currently ACE inhibitors or ARBs are used for preventing progression of microalbuminurea 
to macroalbuminurea and advance stages of nephropathy. These drugs have a large amount 
of adverse effects such as extreme hypotension, hyperkalemia and dry cough which has in 
certain cases becomes sever enough to stimulate tuberculous cough resulting  in wrongful 
antituberculous treatment being prescribed to the patient. In such a scenario it is important 
that another biomarker other than microalbuminurea be found for diabetic hypertensive 
nephropathy which would reveal the development of incipient diabetic nephropathy and a 
specific drug be designed for that biomarker which would have a fewer side effects as it 
would be biomarker specific.( Martin- Gallan, et al., (2003). 
Type 2 diabetic patients, and  same age and sex-matched normal healthy controls were 
recruited from the Sheikh Zayed Hospital, Lahore, Pakistan. Total Urine and urinary 
proteins were estimated and analyzed initially by different protein assays and 1-D SDS 
polyacrylamide gel electrophoresis. The samples were purified further by passing through 
the high abundance protein removal and desalting columns. These serum and urine samples 
from control and diabetic groups before or after thiamine therapy were further analysed by 
2-D liquid chromatographic system in which samples were initially fractionated by 
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Protein name MW 
(KDa) 
PI Function Up or down 
regulated 
ǂ1-Antitrypsin 46,707 5.52 Defense 
response 
+ 
Serotransferrin 
precursor 
77,000 7.19 Transport  
Ceruloplasmin 
Precursor 
122,128 5.64 Transport + 
Hemopexin 51,643 6.96 Transport  
AMBP protein 38,974 6.21 Metabolism - 
Complement factor H 139,034 6.64 Defense 
response 
 
Serum albumin 71,658 6.79 Transport + 
Alpha1-
Antichymotrypsin 
precursor 
47,651 4.6 Defense 
response 
 
Antithrombin-III 52,658  6.41 Defense 
response 
 
Complement 
component C3 
187,046 6.32 Defense 
response 
 
ApoA-1 30,759 5.72 Metabolism - 
Alpha2-Glycoprotein 
1, zinc 
34,223 5.97 Defense 
response 
+ 
Ig gama 1 chain C 
region 
51,628 8.1 Defense 
response 
 
Kininogen precursor 47,853 6.64 Signal 
transduction 
 
B-factor, properdin 68,829 6.48 Metabolism  
Alpha1B-
Glycoprotein 
54,239 5.82 FNA + 
ApoA-IV 45,343 5.37 Metabolism 
 
 
Haptoglobin 
precursor 
31,362 8.65 Transport 
 
 
Clusterin 52,461 6.19 Signal 
transduction 
 
Beta 2-Glycoprotein 1 
precursor 
38,273 8.42 Metabolism  
Complement factor B 85,479 7.06 Defense 
response 
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Protein name MW 
(KDa) 
PI Function Up or down 
regulated 
Complement factor I 65,677 7.87 Defense 
response 
 
Complement 
component C7 
93,457 6.43 Defense 
response 
 
Hepatocellular 
carcinoma associated 
protein TB6 
83,232 5.69 Transport  
Sulfated glycoprotein 2 57,796 6.62 Signal 
transduction 
 
Angiotensinogen 53,121 6.22 Signal 
transduction 
 
Leucine-rich alpha 2-
glycoprotein 
38,154 6.88 FNA  
Transthyretin 
precursor 
15,877 5.71 Metabolism - 
Alpha2-HS-
glycoprotein 
precursor 
39,300 5.64 Metabolism + 
Prostaglandin H2 D-
isomerase precursor 
21,015 8.15 Metabolism  
Calgranulin B 13,234 6.04 Defense 
response 
+ 
Complement 
component 9 
precursor 
63,133 5.53 Defense 
response 
 
Ig alpha -1 chain C 
region 
53,163 6.06 Defense 
response 
 
Inter-alpha-trypsin 
inhibitor heavy chain 
h4 
precursor 
101,179 6.57 Metabolism   
Plasma retinol-
binding protein 
precursor 
22,995  5.95 Signal 
transduction 
 
Epidermal growth 
factor–containing 
fibulin-like 
extracellular matrix 
protein 
54,517  4.99 Signal 
transduction 
 
Hypothetical protein 52,553  7.9 FNA  
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Protein name MW 
(KDa) 
PI Function Up or down 
regulated 
Predicted 
immunoglobulin 
23,530 7.6 FNA
Ig k chain C region 15,170 8.65 Defense 
response 
Beta2-microglobulin 13,706 6.45 Defense 
response 
Dystroglycan 
precursor 
97,520 8.9 Metabolism 
Hypothetical protein 70,309 7.9 FNA
Hypothetical protein 37,651 6.4 FNA
VDBP 52,964 5.2 Transport +
Epididymal secretory 
protein E1 
16,559 8.04 Defense 
response 
Hypothetical protein 
FLJ31320 
67,970 8.49 FNA
Lumican precursor 38,405 6.54 Cell 
Development 
Ig gama4 chain C 
region 
35,941 8.2 Defense 
response 
Alpha 2-Antiplasmin 
precursor 
54,531 6.2 Defense 
response 
ApoA-II precursor 11,168 6.82 Metabolism
Fibrinogen beta chain 
precursor 
55,892 8.66 Metabolism
Hypothetical protein 
FLJ35322 
18,511 6.2 FNA
ApoD 21,262 5.11 Metabolism
Corticosteroid-
binding globulin 
Precursor 
45,112 5.93 Transport 
Novel protein 94,331 5.47 FNA
Vitronectin precursor 54,306 4.6 Defense 
response 
Fibrinogen gama 
chain 
51,479 5.51 Metabolism 
Hypothetical protein 
FLJ22612 
58,511 4.62 FNA
Ig gama2 chain C 
region 
46,032 7.88 Defense 
response 
Table 1. Urinary protein identified in type 2 diabetic patients with macroalbuminuria (Riaz, 
S. 2009, 2010, 2011) 
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chromatofocusing and the selected fractions were further analysed by reverse-phase high 
performance liquid chromatography. The proteins which showed variation between test and 
control samples were identified by mass spectrometry MALDI TOF/TOF and LC MS 
analysis. All the samples belonging to the control and diabetic groups were then analyzed 
by ELISA and estimated the levels of some proteins which were found to vary. (Samreen 
Riaz, 2009,2010, 2011)  
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